This announcement contains inside
information for the purposes of Article 7 of Regulation (EU) No
596/2014 as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018. With the publication of this
announcement via a Regulatory Information Service, this inside
information is now considered to be in the public
domain.
NOT FOR PUBLICATION OR RELEASE IN OR
INTO THE UNITED STATES OR AUSTRALIA, CANADA, JAPAN, NEW ZEALAND,
THE REPUBLIC OF IRELAND OR THE REPUBLIC OF SOUTH AFRICA, OR ANY
PROVINCE OR TERRITORY THEREOF OR TO OR FOR THE ACCOUNT OF ANY
NATIONAL, RESIDENT OR CITIZEN OF THE UNITED STATES OR ANY PERSON
RESIDENT IN AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF
IRELAND OR THE REPUBLIC OF SOUTH AFRICA.
BiVictriX Therapeutics
plc
("BiVictriX",
"BiVictriX Therapeutics" or the "Company")
Result of General
Meeting
Alderley Park,
29 August 2024 - BiVictriX (AIM:
BVX), a drug discovery and development
company applying an innovative, proprietary approach to develop a
new class of highly selective, next generation cancer therapeutics,
bispecific antibody drug conjugates (Bi-Cygni® ADCs), which exhibit superior
potency, whilst reducing treatment-related toxicities,
announces that at the Company's General Meeting ("General Meeting")
held earlier today, all resolutions put to the Company's
shareholders ("Shareholders") were duly passed.
Details of proxy votes received are summarised
below:
|
Resolution
Number
|
Resolution
Name
|
Votes For
|
Votes
Against
|
|
No. of
shares
|
% of shares
voted
|
No. of
shares
|
% of shares
voted
|
|
1
|
Cancellation
Resolution
|
56,143,735
|
99.86
|
80,108
|
0.14
|
|
2
|
Re-registration
Resolution and Adoption of New Articles of Association
|
56,143,735
|
99.86
|
80,108
|
0.14
|
The full text of the resolutions proposed and
passed at the General Meeting can be found in the circular
containing, inter alia,
the Notice of General Meeting, which was published and posted to
Shareholders on 12 August 2024 and is available on the Company's
website https://bivictrix.com (the
"Circular").
AIM
Delisting
Following approval by Shareholders at the
General Meeting, the admission of the ordinary shares of £0.01 each
in the capital of the Company ("Ordinary Shares") to trading on AIM
will be cancelled (the "AIM Delisting"). The AIM Delisting is
expected to take place at 7:00 a.m on 11 September 2024
("Cancellation") and, accordingly, the last day of dealings in
Ordinary Shares on AIM is expected to be 10 September
2024.
Re-registration as a private
company
In accordance with the passing of Resolution 2,
the Company will re-register as a private limited company and adopt
new articles of association, which is expected to take place in the
week commencing 23 September 2024.
Matched
Bargain Facility
To facilitate future shareholder transactions
in the Company's Ordinary Shares, the Company has appointed JP
Jenkins to provide a matched bargain facility, which will be
available upon the date of Cancellation. Upon Cancellation, full
details of the matched bargain facility will be made available to
Shareholders on the Company's website https://bivictrix.com.
Capitalised terms used but not defined in this
announcement shall have the same meaning given to such terms in the
Circular.
For more
information, please contact:
|
BiVictriX
Therapeutics plc
Tiffany Thorn, Chief Executive
Officer
Michael Kauffman, Non-Executive
Chairman
|
Email:
info@bivictrix.com
|
|
SP Angel
Corporate Finance LLP (NOMAD and Broker)
David Hignell, Caroline Rowe (Corporate Finance)
Vadim Alexandre, Rob Rees (Sales and Broking)
|
Tel: +44 (0) 20 3470
0470
|
|
Panmure
Liberum Limited (Joint Broker)
Emma Earl,
Freddy Crossley, Mark Rogers, Rupert Dearden
|
Tel: +44 (0) 20 3100
2000
|
|
ICR
Consilium
Namrata Taak, Lucy Featherstone, Max Bennett,
Emmalee Hoppe
|
Tel: +44 (0) 20 3709
5700
Email:
Bivictrix@consilium-comms.com
|
About BiVictriX Therapeutics plc
BiVictriX (AIM: BVX) is an emerging
biotechnology company leveraging clinical experience and its
proprietary discovery engine to advance a new class of highly
cancer-selective, next-generation precision cancer therapies in one
of the fastest-growing markets in oncology. BiVictriX's
first-in-class Bi-Cygni® Antibody Drug Conjugates ("ADCs") combine
superior efficacy with substantially
improved cancer-selectivity and safety to provide opportunities for
prolonged dosing and greater efficacy in the
clinic. The Company is advancing its
pipeline to deliver the future of cancer care across a broad range
of haematological and solid cancer indications in areas of high
unmet medical need.
Find out more
at www.bivictrix.com and
connect with us on LinkedIn and
Twitter @BiVictriX.
